
ArcDia International Ltd.
ArcDia’s mariAST® is the most promising platform to tackle antibiotic resistance, a growing concern that directly causes 23,000 deaths every year in the US alone, and can soon make many routine operations too risky to perform.
Since 2011, ArcDia’s mariPOC® has been in use for rapid detection of respiratory and gastrointestinal infectious diseases. It is a near-patient technology with ease-of-use, cost-efficiency, high performance and accuracy. mariPOC® test system is IVD CE marked for respiratory tract infections, pharyngitis and gastrointestinal infection testing. mariPOC® is the market leader in Finland in respiratory infection testing with nationwide installation base.
The mariAST® and mariPOC® platforms are based on the proprietary and Nature published ArcDia™ TPX detection technology. The TPX technology allows multianalyte rapid testing with fully automated and random-access test system. The platform is available for clinical diagnostic use, R&D, licensing and distribution.
ArcDia is already distributing to numerous countries but also seeks new partners.
Company history:
- 1998–2003 Fundamental inventions of the TPX technology were made in the Laboratory of Biophysics (University of Turku, Finland) led by professor Erkki Soini.
- 2000 The TPX detection technique was published in Nature Biotechnology.
- 2005–2009 The applicability of TPX detection technique for rapid in vitro testing of infectious diseases was demonstrated in academic projects.
- 2008 ArcDia International Oy Ltd. was founded. mariPOC® product development project began.
- 2011 mariPOC® product was IVD CE marked and introduced to the market.
- 2013 ArcDia received the ISO 13485 certificate.
- 2014 ArcDia Received Frost & Sullivan Award for Point-of-Care Product Leadership.
- 2014 ArcDia moved to a bigger premises in Turku Science Park area.
- 2016 ArcDia released new products: mariPOC®+ software mode, mariPOC® gastro test panel, world’s first bocavirus rapid test and more sensitive 2nd generation influenza A virus test
- 2017 ArcDia launched new mariPOC®Quick StrepA test, faster 2nd generation Pharyn test and new products: world’s first rapid test for coronavirus, and CDI test in concordance with the newest clinical guidelines. mariCloudTM on-line service for real-time epidemiological surveillance was opened.
- 2018 New mariPOC® Quick Flu/RSV test was introduced to Finnish markets and 2019 to international markets